tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Abivax $400M Spot Secondary; price range $62.50-$65.00
PremiumThe FlyAbivax $400M Spot Secondary; price range $62.50-$65.00
16d ago
Abivax announces $400M ADS offering
Premium
The Fly
Abivax announces $400M ADS offering
16d ago
Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
Premium
The Fly
Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
17d ago
Abivax price target raised to $70 from $42 at Piper Sandler
PremiumThe FlyAbivax price target raised to $70 from $42 at Piper Sandler
17d ago
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
Premium
Ratings
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
17d ago
Abivax price target raised to $95 from $33 at Citizens JMP
Premium
The Fly
Abivax price target raised to $95 from $33 at Citizens JMP
17d ago
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
PremiumRatingsAbivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
1M ago
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
Premium
Ratings
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
1M ago
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
Premium
Ratings
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100